Presentation Detail
Speaker
Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
Kevin Choy, BS, BSc, MS, DACVIM (Oncology)
Synopsis
In this presentation, Dr. Sungwon Lim, CEO & Co-Founder of ImpriMed, shares the latest updates from ImpriMed. He will describe ImpriMed's new research on genomic biomarkers for anticancer drug response prediction. Dr. Kevin Choy, a board-certified medical oncologist at Seattle Veterinary Specialists - BluePearl Kirkland, Washington, will present clinical cases of naïve and relapsed Canine lymphoma utilizing ImpriMed's artificial intelligence-driven anticancer drug response predictions.ImpriMed's flagship product, Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed's artificial intelligence (AI) models, trained on real-world clinical outcome data, predict which anticancer drugs are most likely to be effective for a particular dog's lymphoma or leukemia based on comprehensive testing of each patient's live cancer cells and other information about the patient.
